9/10 wound care patients more appropriately triaged with fluorescence information
60% of these 9 patients would have been undertreated while 30% of patients were being overtreated
$1552 Single patient cost savings (USD) due to fluorescence evidence-based treatment plan changes
Fluorescence imaging was used to screen wounds treated with split thickness grafts
These wounds were processed by MEEK/MESH technique for bacterial burden
Fluorescence imaging shows high concentrations of pathogens both in the MEEK silk layer as well as in foam linkers
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2024
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.